2022 Biosimilars Generic Medicine 
European Pharmaceutical Review
AUGUST 25, 2022
Novartis has announced that it intends to separate Sandoz , its generics and biosimilars division into a new publicly traded standalone company. The 100 percent spin-off aims to establish Sandoz as the premier European generics company and a global leader in biosimilars, maximising shareholder value.
Pharmaceutical Technology
DECEMBER 15, 2022
On November 16, 2022, Medicines for Europe (MFE), the generics and biosimilars body, called for EU and national reforms to improve the security of medicine supplies, including tackling the impact of inflation on the security of essential medicine supplies with smart procurement guidelines for medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 14, 2022
For Sandoz, the acquisition gives it a technology platform in an area of the generic medicines market with a relatively high barrier to entry, as developing inhaled medicines poses “comparatively high technical complexity,” according to Sandoz chief executive Richard Saynor.
European Pharmaceutical Review
JULY 29, 2024
The treatment is already authorised in the US, Japan, China, South Korea, Hong Kong, and Israel, based on data from the worldwide Phase III Clarity AD study, of which results were published in November 2022. Tuznue (trastuzumab) for breast and gastric cancer.
Quality Matters
JANUARY 23, 2023
Omnibus Spending Law: Provisions Will Bolster Medicines Supply Chain Insights and Advanced Manufacturing Technologies Investments to create a more resilient medicines supply chain and prepare for future public health emergencies are among key provisions of the mammoth $1.7
Pharmaceutical Technology
FEBRUARY 18, 2023
The company offers generic medicines and biosimilars through Sandoz. The company reported revenues of (US Dollars) US$51,742 million for the fiscal year ended December 2022 (FY2022), a decrease of 2.1% Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR).
Express Pharma
JULY 3, 2023
For decades, Waters has been a trusted partner to many pharma and generics companies operating in India, particularly for small molecule QA/QC. India is known as the ‘Pharmacy of the World’, as the generic medicine supplier for over 200 countries, both developed and emerging markets. How poised are you to leverage them?
Expert insights. Personalized for you.
98 
Let's personalize your content